CN110835376B - 涉及具有强烈降低的受体结合亲和力的细胞因子的融合因子 - Google Patents

涉及具有强烈降低的受体结合亲和力的细胞因子的融合因子 Download PDF

Info

Publication number
CN110835376B
CN110835376B CN201911159381.7A CN201911159381A CN110835376B CN 110835376 B CN110835376 B CN 110835376B CN 201911159381 A CN201911159381 A CN 201911159381A CN 110835376 B CN110835376 B CN 110835376B
Authority
CN
China
Prior art keywords
cells
fusion
cytokines
activity
cytokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201911159381.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN110835376A (zh
Inventor
J·塔威尼尔
J·堡丁克
S·格尔罗
G·尤则
F·保罗
Y·博达特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ghent University
Vlaams Instituut voor Biotechnologie
Centre National de la Recherche Scientifique
Centre Hospitalier Universitaire de Montpellier
University of Montpellier
Original Assignee
Ghent University
Vlaams Instituut voor Biotechnologie
Centre National de la Recherche Scientifique
Centre Hospitalier Universitaire de Montpellier
University of Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ghent University, Vlaams Instituut voor Biotechnologie, Centre National de la Recherche Scientifique, Centre Hospitalier Universitaire de Montpellier, University of Montpellier filed Critical Ghent University
Priority to CN201911159381.7A priority Critical patent/CN110835376B/zh
Publication of CN110835376A publication Critical patent/CN110835376A/zh
Application granted granted Critical
Publication of CN110835376B publication Critical patent/CN110835376B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201911159381.7A 2013-07-18 2014-07-03 涉及具有强烈降低的受体结合亲和力的细胞因子的融合因子 Active CN110835376B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911159381.7A CN110835376B (zh) 2013-07-18 2014-07-03 涉及具有强烈降低的受体结合亲和力的细胞因子的融合因子

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP13306034 2013-07-18
EP13306034.3 2013-07-18
CN201911159381.7A CN110835376B (zh) 2013-07-18 2014-07-03 涉及具有强烈降低的受体结合亲和力的细胞因子的融合因子
CN201480040538.3A CN105705641B (zh) 2013-07-18 2014-07-03 涉及具有强烈降低的受体结合亲和力的细胞因子的融合因子
PCT/EP2014/064227 WO2015007536A2 (en) 2013-07-18 2014-07-03 Fusokines involving cytokines with strongly reduced receptor binding affinities

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480040538.3A Division CN105705641B (zh) 2013-07-18 2014-07-03 涉及具有强烈降低的受体结合亲和力的细胞因子的融合因子

Publications (2)

Publication Number Publication Date
CN110835376A CN110835376A (zh) 2020-02-25
CN110835376B true CN110835376B (zh) 2023-08-04

Family

ID=48906191

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201911159381.7A Active CN110835376B (zh) 2013-07-18 2014-07-03 涉及具有强烈降低的受体结合亲和力的细胞因子的融合因子
CN201480040538.3A Active CN105705641B (zh) 2013-07-18 2014-07-03 涉及具有强烈降低的受体结合亲和力的细胞因子的融合因子

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480040538.3A Active CN105705641B (zh) 2013-07-18 2014-07-03 涉及具有强烈降低的受体结合亲和力的细胞因子的融合因子

Country Status (14)

Country Link
US (4) US10640542B2 (enExample)
EP (2) EP3299466B1 (enExample)
JP (2) JP6580037B2 (enExample)
KR (1) KR102322510B1 (enExample)
CN (2) CN110835376B (enExample)
AU (2) AU2014292371B2 (enExample)
BR (1) BR112016001036B1 (enExample)
CA (1) CA2917937C (enExample)
DK (1) DK3299466T3 (enExample)
ES (2) ES2757501T3 (enExample)
IL (1) IL243451B (enExample)
MX (1) MX375441B (enExample)
SG (2) SG10201808738WA (enExample)
WO (1) WO2015007536A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3371311B1 (en) 2015-11-06 2021-07-21 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
CN109071632B (zh) 2016-02-05 2022-12-30 奥里尼斯生物科学私人有限公司 靶向性治疗剂及其用途
US11248057B2 (en) 2016-03-07 2022-02-15 Vib Vzw CD20 binding single domain antibodies
EP3455245A2 (en) 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutic targeting of non-cellular structures
WO2017194783A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
CN110114368B (zh) 2016-10-24 2024-08-02 奥睿尼斯生物科学私人有限公司 靶向突变干扰素-γ及其用途
KR102642385B1 (ko) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
EP3576765B1 (en) 2017-02-06 2025-07-16 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
CA3050601A1 (en) 2017-02-07 2018-08-16 Vib Vzm Immune-cell targeted bispecific chimeric proteins and uses thereof
CN117924493A (zh) 2017-08-09 2024-04-26 奥里尼斯生物科学有限公司 Clec9a结合剂及其用途
EP3665201A4 (en) 2017-08-09 2021-06-02 Orionis Biosciences, Inc. CD8 BINDERS
EP3664829A4 (en) 2017-08-09 2021-05-05 Orionis Biosciences, Inc. LIAISON OFFICERS AT PD-1 AND PD-L1
WO2019089755A1 (en) 2017-10-31 2019-05-09 Western Oncolytics Ltd. Platform oncolytic vector for systemic delivery
US12655186B2 (en) 2018-01-26 2026-06-16 Orionis Biosciences, Inc. Chimeric protein comprising anti-XCR1 antibody and modified interferon alpha 2
CA3090406A1 (en) 2018-02-05 2019-08-08 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
EP3833391A4 (en) 2018-08-08 2022-08-10 Orionis Biosciences, Inc. ANTI-SIRP1ALPHA CHIMERIC PROTEINS AND USES THEREOF
EP3890773A4 (en) 2018-11-08 2022-11-09 Orionis Biosciences, Inc. MODULATION OF DENDRITIC CELL LINES
JP7689079B2 (ja) 2019-03-28 2025-06-05 オリオニス バイオサイエンシズ，インコーポレイテッド 治療用インターフェロンアルファ１タンパク質
CN113840833B (zh) 2019-03-28 2025-06-17 奥里尼斯生物科学股份有限公司 基于clec9a的嵌合蛋白复合物
WO2020198665A1 (en) 2019-03-28 2020-10-01 Orionis Biosciences, Inc. Fibroblast activation protein binding agents and use thereof
US12544426B2 (en) 2019-06-19 2026-02-10 Orionis Biosciences, Inc. Combination therapy with CD13-targeted chimeric proteins or chimeric protein complexes
CA3185087A1 (en) * 2020-07-07 2022-01-13 Nikolai Kley Immunostimulatory adjuvants
JP2023552289A (ja) 2020-11-19 2023-12-15 カリヴィル イムノセラピューティクス， インコーポレイテッド 腫瘍微小環境リモデリングによる腫瘍溶解性免疫療法
EP4329786A4 (en) 2021-04-30 2024-12-11 KaliVir Immunotherapeutics, Inc. Oncolytic viruses for modified mhc expression
WO2024112814A1 (en) * 2022-11-21 2024-05-30 Wisconsin Alumni Research Foundation SYNTHETIC IL6-IL1β FUSION CYTOKINE FOR PROMOTING T CELL CYTOTOXIC FUNCTION, T CELL PROLIFERATION, AND TUMORICIDAL ACTIVITY

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044394A2 (en) * 2000-11-29 2002-06-06 University Of Southern California Targetet retoviral vectors for cancer immunotherapy
CN1377892A (zh) * 2001-04-04 2002-11-06 上海华晨生物技术研究所 细胞因子基因修饰的抗原提呈细胞/肿瘤细胞偶联物、其制法和用途
CN1956997A (zh) * 2004-05-21 2007-05-02 爱吉瑞克斯有限公司 嵌合型可溶性超il－11和其应用
WO2008124086A2 (en) * 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
CN102372780A (zh) * 2010-08-23 2012-03-14 上海市计划生育科学研究所 抗人绒毛膜促性腺激素抗体-白介素2融合蛋白的制备及其应用
CN102712697A (zh) * 2009-11-02 2012-10-03 加利福尼亚大学董事会 用于细胞因子递送的穹窿体复合物
CN102917709A (zh) * 2009-12-23 2013-02-06 格兰达利斯有限公司 弗林蛋白酶敲减和gm-csf增强的（fang）癌症疫苗

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0489116B1 (en) * 1989-08-22 1994-04-06 Immunex Corporation Fusion proteins comprising gm-csf and il-3
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5914254A (en) 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
WO2001010912A1 (en) * 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
EP1454138B1 (en) * 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokines with modulated selectivity
DE602004031341D1 (de) * 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
EP1812038A1 (en) 2004-11-18 2007-08-01 VIB vzw Fibronectin iii domain as leptin receptor antagonists
WO2006115800A2 (en) 2005-04-15 2006-11-02 The Regents Of The University Of California Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha
US7947265B2 (en) * 2006-08-02 2011-05-24 Mcgill University Fusion proteins and methods for modulation of immune response
WO2009003145A1 (en) 2007-06-26 2008-12-31 University Of Miami Antibody-endostatin fusion protein and its variants
ES2536772T3 (es) 2007-09-21 2015-05-28 The Regents Of The University Of California El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales
US8334101B2 (en) 2008-09-26 2012-12-18 University Of Massachusetts Intracellular DNA receptor
CA2749558C (en) 2008-12-08 2019-01-15 Complix Nv Single-chain antiparallel coiled coil proteins
RU2583876C2 (ru) 2009-08-17 2016-05-10 Роше Гликарт Аг Иммуноконъюгаты направленного действия
CN102497885A (zh) 2009-09-10 2012-06-13 赛托斯生物技术公司 白介素-1β突变蛋白偶联物在糖尿病治疗中的用途
MX2012012229A (es) * 2010-04-22 2013-03-05 Yissum Res Dev Co Leptinas de alta afinidad y antagonistas de leptina.
WO2012170072A1 (en) 2011-06-06 2012-12-13 Immungene, Inc. Engineered antibody-tnfsf member ligand fusion molecules
CN104203982B (zh) 2011-10-28 2018-08-31 特瓦制药澳大利亚私人有限公司 多肽构建体及其用途
WO2013107791A1 (en) * 2012-01-20 2013-07-25 Vib Vzw Targeted mutant alpha-helical bundle cytokines
PL2822575T3 (pl) 2012-03-03 2020-08-10 Immungene, Inc. Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu
PE20170908A1 (es) * 2014-10-29 2017-07-12 Teva Pharmaceuticals Australia Pty Ltd VARIANTES DE INTERFERON a2b

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044394A2 (en) * 2000-11-29 2002-06-06 University Of Southern California Targetet retoviral vectors for cancer immunotherapy
CN1377892A (zh) * 2001-04-04 2002-11-06 上海华晨生物技术研究所 细胞因子基因修饰的抗原提呈细胞/肿瘤细胞偶联物、其制法和用途
CN1956997A (zh) * 2004-05-21 2007-05-02 爱吉瑞克斯有限公司 嵌合型可溶性超il－11和其应用
WO2008124086A2 (en) * 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
CN102712697A (zh) * 2009-11-02 2012-10-03 加利福尼亚大学董事会 用于细胞因子递送的穹窿体复合物
CN102917709A (zh) * 2009-12-23 2013-02-06 格兰达利斯有限公司 弗林蛋白酶敲减和gm-csf增强的（fang）癌症疫苗
CN102372780A (zh) * 2010-08-23 2012-03-14 上海市计划生育科学研究所 抗人绒毛膜促性腺激素抗体-白介素2融合蛋白的制备及其应用

Also Published As

Publication number Publication date
JP2016525516A (ja) 2016-08-25
CN105705641A (zh) 2016-06-22
AU2014292371A1 (en) 2016-02-04
BR112016001036B1 (pt) 2023-02-23
EP3299466B1 (en) 2019-09-11
EP3022305B1 (en) 2017-11-01
JP2020002155A (ja) 2020-01-09
US20180155404A1 (en) 2018-06-07
US10640542B2 (en) 2020-05-05
IL243451A0 (en) 2016-03-31
JP6853317B2 (ja) 2021-03-31
US20230054612A1 (en) 2023-02-23
US11358997B2 (en) 2022-06-14
IL243451B (en) 2019-10-31
KR102322510B1 (ko) 2021-11-08
DK3299466T3 (da) 2019-11-18
CN110835376A (zh) 2020-02-25
WO2015007536A2 (en) 2015-01-22
CA2917937A1 (en) 2015-01-22
SG10201808738WA (en) 2018-11-29
KR20160108291A (ko) 2016-09-19
JP6580037B2 (ja) 2019-09-25
SG11201600163VA (en) 2016-02-26
CA2917937C (en) 2022-11-01
US20190010199A1 (en) 2019-01-10
AU2018203868B2 (en) 2019-12-05
ES2657060T3 (es) 2018-03-01
EP3022305A2 (en) 2016-05-25
US12410222B2 (en) 2025-09-09
WO2015007536A3 (en) 2015-03-19
US20260167687A1 (en) 2026-06-18
CN105705641B (zh) 2021-07-13
MX2016000611A (es) 2016-09-29
AU2018203868A1 (en) 2018-06-21
ES2757501T3 (es) 2020-04-29
EP3299466A1 (en) 2018-03-28
MX375441B (es) 2025-03-06
AU2014292371B2 (en) 2018-03-29
HK1252831A1 (en) 2019-06-06
BR112016001036A2 (pt) 2017-10-24

Similar Documents

Publication Publication Date Title
US12410222B2 (en) Fusokines involving cytokines with strongly reduced receptor binding affinities
AU2015301936B2 (en) Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases
CN106795213B (zh) 选择性地活化调节性t细胞用于治疗自身免疫病的分子
CN110437339A (zh) 一种以白介素15为活性成分的融合蛋白型药物前体
JP4842128B2 (ja) 新規多機能性サイトカイン
CN108602871A (zh) 用于治疗自身免疫疾病的选择性地活化调节性t细胞的分子
US20110038854A1 (en) Strategy for homo- or hetero-dimerization of various proteins in solution and in cell
JP2024543991A (ja) Ｉｌ１０バリアントおよびその使用
JP2025504050A (ja) Ｐｄ１抗体とインターロイキン２の融合により形成される二官能性分子
Zhan et al. Fusion of HSA influences TNF-α neutralizing activity of shTNFRs
HK1252831B (en) Fusokines involving cytokines with strongly reduced receptor binding affinities
JP2024520569A (ja) ｓＰＤ－１及びＩＬ－１５を有する二重特異性Ｆｃ融合タンパク質
HK1225069A1 (en) Fusokines involving cytokines with strongly reduced receptor binding affinities
HK1225069B (en) Fusokines involving cytokines with strongly reduced receptor binding affinities
Xiong et al. Cloning and expression of rabbit interleukin-15
JP3689111B2 (ja) インターロイキン１５

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant